The lowest price of more than 3 billion varieties is refreshed.

Recently, Shaanxi Province Public Resources Trading Center issued "newly approved drug-related information", Cinda Bio's Beval zhu sing-net price was announced, the price of 1188 yuan / bottle (4ml: 100mg).
June 19 this year, Cinda Bio's Bevalzhu zuma biosimilar drug obtained the drug approval certificate, officially obtained the State Drug Administration approved the listing, this is China's second domestic beivalzumab biosimilar drug.
data show that bevazumab is an anti-tumor angiogenesis inhibitor that blocks the growth of new blood vessels in tumors, while the growth and metastasis of tumor cells are greatly related to the generation of new blood vessels, the new blood vessels are the way of tumor nutrition supply, bevele supreminate can block the binding between receptors to inhibit tumor angiogenesis.
December 9, 2019, Qilu Pharmaceutical Co., Ltd. developed the Bevalzhu monoimmune injection (commodity name: Anda) was approved for listing, which is the first domestic approved Bevazhu zuma biosimilar drug.
data show that Roche's BevalZumab was approved by the CFDA in 2010 for injections of 100mg (4ml) and 400mg (16ml).
Seiberan in the Minnet database query found that the sales of bewar zhusssiny in 2019 in the national public hospital terminals showed 3.43 billion yuan, 2015 to 2019 has maintained an upward trend.
December 2019, Qilu Pharmaceuticals' domestic betovastatin-on-the-net quickly grabbed 0.26 percent of the market share from Roche.
this year, with Cinda Bio's hanging network and Qilu Pharmaceuticals to further promote the release, domestic similar drugs may eat into Roche's original research more markets.
Roche's full-year revenue was CHF 61.5 billion, up 8% year-on-year, with revenues from the pharmaceutical sector at SFr48.5 billion and the diagnostics division at SFr12.9 billion, up 1 percent.
in specific products, anti-tumor "three swordsmen" Bevalzumab 7,073 million Swiss francs (equivalent to 52.9 billion yuan), up 4% YoY, qutozhuzumab (60.39 million, -12%) and litoxiin (6.477 billion, -4%) were basically stable.
Roche's earnings performance was "good and bad" - breaking Pfizer's four-year dominance to number one in the US's annual list of the world's top 50 pharmaceutical companies.
it is understood that bevalo-beadmonotatisisis is still Roche's best-selling products, accounting for 15% of the company's total drug revenue, but as quralm and rituximatod has experienced, in the next few years, bevalo zumas also face competition from biologically similar drugs.
over 1.5 billion varieties, once again reduced the price of the original research drug Bevalu singtag (Amvitin) (100mg:4ml) list price of 5398 yuan, its price on July 19, 2017 after entering health insurance reduced to 1998 yuan (100mg:4ml/bottle).
cut prices again after the 2019 health insurance renewal, although the price has not been announced, but the timing of the renewal talks coincides with the launch of Qilu's first biosimilar, a new round of price cuts is inevitable.
According to the bidding information of Theinner.com, on January 9, Anvetin (4ml:100mg) won the bid price of RMB1934.26 in Fujian, which is for reference only.
December 17, 2019, Qilu Pharmaceuticals declared the Bevalu bead sing-only injection (specs: 4ml: 0.1g) officially for 1266 yuan / branch of the network sales, compared to the latest bid of the beta beads single antigen research 1934.26 yuan / 4ml: 100mg, a decrease of 34.55%. After the
, Qilu in many provinces are 1198 yuan / bottle / 100mg:4ml price net, the price became the next listing of pharmaceutical companies pricing ceiling.
this time, Cinda Bio to 1188 yuan / bottle (4ml: 100mg) price hanging net, and then create the lowest market price of this variety.
drug data show that in the domestic research and development competition of beifa-beaded anti-drug similar drugs, the declaration enterprise has reached more than 20, in addition to Qilu Pharmaceutical and Cinda Bio, in April 2020, Hengrui Pharmaceutical's Bevala Zuma anti-biosimilar drug listing application was accepted by CDE;
in addition to the head enterprises, the variety also has Fuhong Hanxuan, Shandong Bo'an biological technology, Dongyi Pharmaceuticals, Tianguang real biology, Bai Otai biology, Anhui Anke and other more than 10 enterprises are being declared.
in recent years, domestic pharmaceutical companies continue to upgrade from generic to innovative drugs to explore, but still due to the rapid changes in the policy environment, lack of research and development capacity and other reasons, even in the field of innovative drugs there is a "high level of repeated construction" situation.
the heavy-duty biosimilar drug headed by Beval-Zhu-Sing is a typical case - because of the rapid overseas release speed and higher sales amount attracted the attention of many domestic research and development enterprises, coupled with biosimilars more in line with domestic enterprises from imitation to innovative ideas, resulting in domestic pharmaceutical companies in such heavy biological similar drugs in the competition for research and development is extremely fierce.
at present, the competition pattern of the first echelon of Beval-Zhu sing-sing-sing-sing-resistant has been relatively clear, the subsequent successful listing of enterprises, product pricing has been lower than previously expected, now Cinda Bio's product pricing as low as 1188 yuan / bottle (4ml: 100mg), follow-up products taking into account research and development costs, production costs, circulation costs, national taxes and corporate profits and other conditions, combined with fierce market competition, pricing or will fall below 10000 yuan.
.